Breaking News
June 20, 2018 - Clinical trial targets metastatic colorectal cancer with new combination therapy
June 20, 2018 - Researchers discover pesticide-free way to limit mosquitoes and reduce spread of West Nile virus
June 20, 2018 - Persistent psychological stress contributes to development and progression of vision loss
June 20, 2018 - Study introduces novel strategy to obtain reasonable drug cost estimates for cost-effectiveness analyses
June 20, 2018 - Does Salt Water Help Your Cut? And Other Health Myths of Summer
June 20, 2018 - Scientists help identify genetic markers for prostate cancer in global DNA download
June 19, 2018 - Common ingredient in toothpaste and hand wash could contribute to antibiotic resistance
June 19, 2018 - WHO launches multiyear campaign to eliminate use of trans fat
June 19, 2018 - Scientists could build better drugs by learning from bacteria-derived molecules
June 19, 2018 - Comparative silence between firing spikes of neurons reveals what they are really up to
June 19, 2018 - JAK inhibitors associated with aggressive lymphoma
June 19, 2018 - SetPoint announces positive long-term results of bioelectronic medicine to treat rheumatoid arthritis
June 19, 2018 - Hypnosis may help reduce fear, anxiety in children undergoing treatment for cancer
June 19, 2018 - Scientists point to potentially promising treatment target for deadly brain cancers
June 19, 2018 - After opioid overdose, only 30 percent get medicine to treat addiction
June 19, 2018 - Patients with mild Alzheimer’s disease over age 65 continue to derive benefit from DBS-f treatment
June 19, 2018 - Microbiotica partners with University of Adelaide to develop defined bacterial product for ulcerative colitis
June 19, 2018 - Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus
June 19, 2018 - Autism is not linked to eating fish in pregnacy
June 19, 2018 - Scientists create universal assembly method to enhance cancer therapy and diagnostics
June 19, 2018 - FDA provides guidance on Novus Therapeutics’ development path for OP-02 to treat otitis media
June 19, 2018 - Scientists discover new mechanism controlling multiple sclerosis risk
June 19, 2018 - Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections
June 19, 2018 - Study finds combined risk of death and developing cancer to be lowest in light drinkers
June 19, 2018 - Novel app teaches users how to stop life-threatening bleeding and save lives
June 19, 2018 - Single blood sample can provide adequate confirmation of diabetes
June 19, 2018 - New stimulation method increases hope for improving disorders of consciousness
June 19, 2018 - FDA Issues Complete Response Letter for Duobrii (halobetasol propionate and tazarotene) Lotion
June 19, 2018 - Defining the biology of autism
June 19, 2018 - Researchers use optogenetics to shape tissues
June 19, 2018 - Scientists discover genetic causes underlying group of related infant cancers
June 19, 2018 - Innovative digital home testing kit benefits patients with kidney conditions
June 19, 2018 - New guidance on selection and evaluation of wearable devices for use in regulatory clinical trials
June 19, 2018 - Researchers understand the role of brain’s ‘reward circuit’ in autism spectrum disorder
June 19, 2018 - Researchers propose new strategy to combat micro-pollutants in water
June 19, 2018 - Illicit Opioid Trade Up With Restrictions on Hydrocodone
June 19, 2018 - New 3-D imaging analysis technique could lead to improved arthritis treatment
June 19, 2018 - Study finds increased risk of mortality in people with cold agglutinin disease in five years after diagnosis
June 19, 2018 - Psychologists can play important role in treating alcohol problems
June 19, 2018 - Study finds elevated risk of congenital defects in lithium-exposed infants
June 19, 2018 - Test-Taking Can Be Tough for Kids With Vision Problems
June 19, 2018 - Injections for knee osteoarthritis—’subtle but significant’ impact of revisions in clinical practice guidelines
June 19, 2018 - Researchers develop new approach to assess effectiveness of Men B vaccine
June 19, 2018 - Study shows link between financial literacy and hospitalization risk in older adults
June 19, 2018 - If you’ve got hep C, spitting can be a felony
June 19, 2018 - New study examines how the brain plays role in rheumatoid arthritis inflammation
June 19, 2018 - Researchers discover new defense mechanism against oxygen radicals
June 19, 2018 - WVU researcher aims to produce updated whooping cough vaccine
June 19, 2018 - Scientists develop novel computational framework to support personalized cancer treatment
June 19, 2018 - Rate of dementia on the decline—but beware of growing numbers
June 19, 2018 - Microglia play protective role in response to retinal detachment, shows study
June 19, 2018 - Technology breakthrough could enable detection of fetal genetic abnormalities in early pregnancy
June 19, 2018 - Novel chip can be used to identify rhinovirus strains as cause of asthma
June 19, 2018 - Effects of in vitro fertilization depend on genetic variation inherited from parents
June 19, 2018 - Heart attack patients unable to resume work report depression and financial hardship
June 19, 2018 - Study combines gene editing and stem cell technologies to predict person’s risk for heart disease
June 19, 2018 - Weight loss of 20% or greater results in better outcomes for overweight, obese adults with knee osteoarthritis
June 19, 2018 - Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
June 19, 2018 - Study predicts most people with earliest Alzheimer’s signs won’t develop dementia associated with the disease
June 19, 2018 - Abnormal sleep duration linked to metabolic syndrome in new study
June 19, 2018 - Researchers develop new method to preserve fertility in boys with prepubertal cancer
June 19, 2018 - Late onset of diabetes could be indicative of pancreatic cancer
June 19, 2018 - WHO releases new International Classification of Diseases (ICD-11)
June 19, 2018 - Skin tone makes big difference in diagnosis and treatment of dermatologic conditions
June 19, 2018 - After addiction, the long road back to good health
June 19, 2018 - High blood pressure could be an early sign of dementia
June 19, 2018 - Innovative drugs and new European treatment guidelines refine, improve MS therapy
June 19, 2018 - BIDMC scientists develop new tool to benefit patients with HCV-associated liver failure
June 19, 2018 - Diabetes diagnosis may come with increased risk of pancreatic cancer for African-Americans, Latinos
June 19, 2018 - Personalized Goals, Cash Motivate Heart Patients to Exercise
June 19, 2018 - Nipah Virus (NiV) | CDC
June 19, 2018 - Genomics offers new treatment options for infants with range of soft tissue tumors
June 18, 2018 - Study shows how moderate consumption of alcohol can protect the heart
June 18, 2018 - Gene editing technology predicts heart disease risk
June 18, 2018 - Who Will and Who Won’t Get the Flu?
June 18, 2018 - Research shows effective responses to online feedback
June 18, 2018 - Scientists to focus on big data and genetics to identify risk factors for dementia
June 18, 2018 - Ultrasound-based technology for assessing overweight adolescents with liver disease
June 18, 2018 - Osteochondral knee defect treated using cell technology
June 18, 2018 - New clinical trial finds no evidence to support use of tamsulosin for kidney stones
Genetic testing of prostate tumors could identify likely responders to immunotherapy

Genetic testing of prostate tumors could identify likely responders to immunotherapy

image_pdfDownload PDFimage_print

Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

Developing a genetic test to pick out these men could speed up the path of immunotherapy into use for prostate cancer patients.

A major clinical trial earlier this month became the first to show that immunotherapy could work in advanced prostate cancer – but only for about 10 per cent of men.

Now the new study, involving scientists at The Institute of Cancer Research, London, has discovered that testing the genetics of prostate tumors could identify the likely responders.

The research, published today (Thursday) in the prestigious journal Cell, found that men whose tumors had a distinct pattern of genetic changes could be much more likely to benefit from immunotherapy than otherwise.

The study was supported by funders including the Prostate Cancer Foundation and Stand Up 2 Cancer.

Scientists at The Institute of Cancer Research (ICR) worked with colleagues at the University of Michigan in the US to analyze tumor DNA collected internationally from 360 men with advanced prostate cancer that had spread.

They found that the tumors of 7 per cent of these men were missing both copies of a gene called CDK12, a trait that was linked with a unique pattern of additional genetic changes.

Tumors with this genetic profile contained a higher number of immune cells than other forms of advanced prostate cancer.

They also had a higher number of protein fragments on their surface, called neoantigens, which flag tumor cells to the immune system. Tumors that are associated with large numbers of immune cells and neoantigens often respond better to immunotherapy, presumably because the immune system has already begun to recognize elements of the cancer as foreign.

In a small pilot clinical study carried out in the US as part of the research, two out of four men with advanced prostate cancer whose tumors had CDK12-linked genetic changes responded remarkably well to the immunotherapy drug pembrolizumab.

It follows the results of a clinical trial led by the ICR and The Royal Marsden NHS Foundation Trust which showed pembrolizumab could benefit a subset of patients with advanced prostate cancer who had run out of existing treatment options.

In the new study, the pattern of genetic changes linked with the missing copies of the CDK12 gene was distinct from other, previously identified genetic subtypes of prostate cancer, making this an entirely separate form of the disease.

If the research can be replicated in larger numbers of patients, it could lead to introduction of a genetic test as a precursor to offering immunotherapy.

In future, CDK12 could also be explored as a genetic weakness that could be targeted by new precision drugs for prostate cancer. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, said:

“Immunotherapy works for a relatively small group of men with advanced prostate cancer – but when it works, it really works. If we can identify in advance who will benefit, then it should accelerate the passage of immunotherapy into routine use for patients.

“Our new study has revealed a distinct group of men with advanced prostate cancer whose tumors have biological features that could make them likely to respond to immunotherapy drugs such as pembrolizumab.

“We now need larger clinical studies to further study the benefit of immunotherapy in this group of patients. In the future, a genetic test could help pick out men with this particular set of genetic changes, so that they can be considered for immunotherapy.”

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

“Increasing our understanding of the biological and genetic features of cancer is vital in the search for smarter, kinder cancer treatments.

“It’s exciting that this study may have cracked the underlying biology of why only some men with prostate cancer appear to respond well to immunotherapy.

“I look forward to this work being taken forward as soon as possible with the aim of ensuring that some men with prostate cancer can start having the same kinds of benefit from immunotherapy that we are seeing in other tumor types.”

Howard Soule, Ph.D., executive vice president and chief science officer of the Prostate Cancer Foundation, said:

“The identification of CDK12 loss as a possible biomarker for identifying prostate cancer patients who may respond to checkpoint immunotherapy is a hugely significant finding, as researchers have struggled with how to effectively use immunotherapy in prostate cancer for many years.

Source:

https://www.icr.ac.uk/news-archive/gene-testing-could-identify-men-with-prostate-cancer-who-may-benefit-from-immunotherapy

Tagged with:

About author

Related Articles